UNSPSC 51362501: Amperozide

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C23H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M2W3TAG39, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but generally known as amperozide, which bears US NIH Compound Identifier 73333. Amperozide most often comes in base and hydrochloride forms. European Medicines Agency schedules Amperozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05483MIG.

UNSPSC 51362501 Amperozide, a Commodity code, nominally identifies a single pharmaceutical product, but recent state and local solicitations reveal that jurisdictions use this code to procure a broader mix of prescription medications, over-the-counter products, and related pharmaceutical systems through competitive bidding and cooperative purchasing vehicles. The work being solicited ranges from direct purchase of specific drug formulations (including naloxone and drug deactivation systems) to participation in multi-state pharmaceutical supply agreements with fixed pricing, pricing flexibility options, and compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions; Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear in recent activity.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries and vendor-funded shipping to the county's community health building. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, soliciting information about direct contracting capacity and outcomes-based pricing models prior to formal RFP issuance. MMCAP issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent across administrative compliance, EDI capability, and administrative fee structure.